Pharmaceuticals, Biotechnology and Life Sciences
Ironwood has increased total revenue by 16% year-over-year to $80 million, driven primarily by U.S. LINZESS collaboration revenue of $71 million.
– Phase IIIb study met all primary and secondary endpoints
with statistical significance and demonstrated that linaclotide improved
the overall abdominal symptoms of bloating, pain and discomfort in
adults with IBS-C –
– Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019 – – First quarter…
– “When-issued” trading of CYCN expected to begin on Nasdaq on March
18, 2019 –
– Separation completion expected April 1, 2019 –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ironwood
Pharmaceuticals, Inc. (Nasdaq: IRWD…
Ironwood Pharmaceuticals and Allergan have been testing an irritable bowel syndrome with constipation (IBS-C) drug, a formulation of linaclotide colonic…